NR4A1 and breast cancer: Hormone receptor positive (HR)/PR+ patients can be successfully treated with ER antagonists, such as tamoxifen, or by aromatase inhibitors [4], while HER+ BC patients are treated with antibodies or different molecules targeting the HER2 pathways, such as trastuzumab, pertuzumab, and lapatinib [5].